近年来，应用细胞因子诱导的杀伤细胞（cytokine induced killer cell，CIK细胞）进行恶性肿瘤治疗的临床试验在国内外陆续开展，CIK细胞免疫治疗在临床治疗中表现出明显优于其他过继性免疫治疗的强大优势，因而越来越广泛地被应用到临床肿瘤治疗中。CIK细胞可作为单独的治疗方法，也可与外科手术、放疗、化疗结合进行综合治疗。本文追踪国内外的研究进展，对CIK细胞的来源及表型、活化及扩增、抗肿瘤作用机制、新的技术方法及目前国际临床试验现状等诸多方面作一评述，并对目前CIK临床应用中存在的问题、规范化管理、质量监控、疗效评估和未来发展方向等进行探讨。

In recent years, the clinical trials on using cytokine induced killer (CIK) cells for solid tumor therapy have been launched worldwide. CIK cell immunotherapy has showed great advantages in clinical treatment compared with other adoptive immunity therapy, which is therefore more and more widely used in adoptive immunotherapy of tumors. CIK cells can be used alone or in combination with surgery, radiotherapy and chemotherapy for comprehensive treatment. In this article, we keep a track of research progress both home and abroad, briefly introduce the source, phenotype, activation and amplification of the CIK cells, and summarize their anti-tumor mechanisms, new techniques and methods, and current status of international clinical trials from several aspects. Some open questions about clinical treatment, standard management, quality monitoring, therapeutic evaluation and future directions are also explored.

国家自然科学基金资助项目（No. 39270765）；黑龙江省自然科学基金资助项目（No. D201171）